Skip to main content
Erschienen in: Journal of Thrombosis and Thrombolysis 1/2008

01.02.2008

Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues

verfasst von: Brian F. Gage, Lawrence J. Lesko

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 1/2008

Einloggen, um Zugang zu erhalten

Abstract

Using pharmacogenetics-based therapy, clinicians can estimate the therapeutic warfarin dose by genotyping patients for single nucleotide polymorphisms (SNPs) that affect warfarin metabolism or sensitivity. SNPs in the cytochrome P450 complex (CYP2C9) affect warfarin metabolism: patients who have the CYP2C9*2 and/or CYP2C9*3 variants metabolize warfarin slowly and are more likely to have an elevated International Normalized Ratio INR or to hemorrhage during warfarin initiation than patients without these variants. SNPs in vitamin K epoxide reductase (VKORC1) correlate with warfarin sensitivity. Patients who are homozygous for a common VKORC1 promoter polymorphism, −1639 G>A (also designated as VKOR 3673, haplotype A, or haplotype*2), are warfarin sensitive and typically require lower warfarin doses. By providing an estimate of the therapeutic warfarin dose, pharmacogenetics-based therapy may improve the safety of anticoagulant therapy. To improve drug safety, the FDA updates labels of previously approved drugs as new clinical and genetic evidence accrues. The labels of medical products serve to inform prescribers and patients about potential ways to improve the benefit/risk ratio and/or optimize doses of medical products. On August 16, 2007, the FDA updated the label of warfarin to include information on pharmacogenetic testing and to encourage, but not require, the use of this information in dosing individual patients initiating warfarin therapy. The FDA completed the label update in August 2007.
Literatur
1.
Zurück zum Zitat White RH, Beyth RJ, Zhou H, Romano PS (1999) Major bleeding after hospitalization for deep-venous thrombosis. Am J Med 107:414–424PubMedCrossRef White RH, Beyth RJ, Zhou H, Romano PS (1999) Major bleeding after hospitalization for deep-venous thrombosis. Am J Med 107:414–424PubMedCrossRef
2.
Zurück zum Zitat Landefeld SC, Beyth R (1993) Anticoagulant-related bleeding: clinical epidemiology, prediction and prevention. Am J Med 95:315–328PubMedCrossRef Landefeld SC, Beyth R (1993) Anticoagulant-related bleeding: clinical epidemiology, prediction and prevention. Am J Med 95:315–328PubMedCrossRef
3.
Zurück zum Zitat Fihn SD, McDonell M, Martin D et al (1993) Risk factors for complications of chronic anticoagulation. A multicenter study. Ann Intern Med 118:511–520PubMed Fihn SD, McDonell M, Martin D et al (1993) Risk factors for complications of chronic anticoagulation. A multicenter study. Ann Intern Med 118:511–520PubMed
4.
Zurück zum Zitat Douketis JD, Foster GA, Crowther MA, Prins MH, Ginsberg JS (2000) Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Arch Intern Med 160:3431–3436PubMedCrossRef Douketis JD, Foster GA, Crowther MA, Prins MH, Ginsberg JS (2000) Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Arch Intern Med 160:3431–3436PubMedCrossRef
5.
Zurück zum Zitat Beyth RJ, Quinn L, Landefeld CS (2000) A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. A randomized, controlled trial. Ann Intern Med 133:687–695PubMed Beyth RJ, Quinn L, Landefeld CS (2000) A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. A randomized, controlled trial. Ann Intern Med 133:687–695PubMed
6.
Zurück zum Zitat Linkins LA, Choi PT, Douketis JD (2003) Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 139:893–900PubMed Linkins LA, Choi PT, Douketis JD (2003) Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 139:893–900PubMed
7.
Zurück zum Zitat Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S (2007) Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 115:2689–2696PubMedCrossRef Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S (2007) Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 115:2689–2696PubMedCrossRef
8.
Zurück zum Zitat Hirsh J, Fuster V, Ansell J, Halperin JL (2003) American heart association/american college of cardiology foundation guide to warfarin therapy. Circulation 107:1692–1711PubMedCrossRef Hirsh J, Fuster V, Ansell J, Halperin JL (2003) American heart association/american college of cardiology foundation guide to warfarin therapy. Circulation 107:1692–1711PubMedCrossRef
9.
Zurück zum Zitat Ezekowitz MD, James KE, Radford MJ, Rickles FR, Redmond N (1999) Initiating and maintaining patients on warfarin anticoagulation: the importance of monitoring. J Cardiovasc Pharmacol Ther 4:3–8PubMedCrossRef Ezekowitz MD, James KE, Radford MJ, Rickles FR, Redmond N (1999) Initiating and maintaining patients on warfarin anticoagulation: the importance of monitoring. J Cardiovasc Pharmacol Ther 4:3–8PubMedCrossRef
10.
Zurück zum Zitat Ansell J, Hirsh J, Dalen J et al (2001) Managing oral anticoagulant therapy. Chest 119:22S–38SPubMedCrossRef Ansell J, Hirsh J, Dalen J et al (2001) Managing oral anticoagulant therapy. Chest 119:22S–38SPubMedCrossRef
11.
Zurück zum Zitat Redman AR (2001) Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing. Pharmacotherapy 21:235–242PubMedCrossRef Redman AR (2001) Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing. Pharmacotherapy 21:235–242PubMedCrossRef
12.
13.
Zurück zum Zitat Margaglione M, Colaizzo D, D’Andrea G et al (2000) Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost 84:775–778PubMed Margaglione M, Colaizzo D, D’Andrea G et al (2000) Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost 84:775–778PubMed
14.
Zurück zum Zitat Gage BF, van Walraven C, Pearce L et al (2004) Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 110:2287–2292PubMedCrossRef Gage BF, van Walraven C, Pearce L et al (2004) Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 110:2287–2292PubMedCrossRef
15.
Zurück zum Zitat Taube J, Halsall D, Baglin T (2000) Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 96:1816–1819PubMed Taube J, Halsall D, Baglin T (2000) Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 96:1816–1819PubMed
16.
Zurück zum Zitat Loebstein R, Yonath H, Peleg D et al (2001) Interindividual variability in sensitivity to warfarin-nature or nurture? Clin Pharmacol Ther 70:159–164PubMedCrossRef Loebstein R, Yonath H, Peleg D et al (2001) Interindividual variability in sensitivity to warfarin-nature or nurture? Clin Pharmacol Ther 70:159–164PubMedCrossRef
17.
Zurück zum Zitat Sanderson S, Emery J, Higgins J (2005) CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med 7:97–104PubMedCrossRef Sanderson S, Emery J, Higgins J (2005) CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med 7:97–104PubMedCrossRef
18.
Zurück zum Zitat Voora D, Eby C, Linder MW et al (2005) Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb Haemost 93:700–705PubMed Voora D, Eby C, Linder MW et al (2005) Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb Haemost 93:700–705PubMed
19.
Zurück zum Zitat Higashi MK, Veenstra DL, Kondo LM et al (2002) Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287:1690–1698PubMedCrossRef Higashi MK, Veenstra DL, Kondo LM et al (2002) Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287:1690–1698PubMedCrossRef
20.
Zurück zum Zitat Allabi AC, Gala JL, Horsmans Y et al (2004) Functional impact of CYP2C95, CYP2C96, CYP2C98, and CYP2C911 in vivo among black Africans. Clin Pharmacol Ther 76:113–118PubMedCrossRef Allabi AC, Gala JL, Horsmans Y et al (2004) Functional impact of CYP2C95, CYP2C96, CYP2C98, and CYP2C911 in vivo among black Africans. Clin Pharmacol Ther 76:113–118PubMedCrossRef
21.
Zurück zum Zitat Kidd RS, Curry TB, Gallagher S, Edeki T, Blaisdell J, Goldstein JA (2001) Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics 11:803–808PubMedCrossRef Kidd RS, Curry TB, Gallagher S, Edeki T, Blaisdell J, Goldstein JA (2001) Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics 11:803–808PubMedCrossRef
22.
Zurück zum Zitat Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW (2004) Identification of the gene for vitamin K epoxide reductase. Nature 427:541–544PubMedCrossRef Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW (2004) Identification of the gene for vitamin K epoxide reductase. Nature 427:541–544PubMedCrossRef
23.
Zurück zum Zitat Rost S, Fregin A, Ivaskevicius V et al (2004) Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427:537–541PubMedCrossRef Rost S, Fregin A, Ivaskevicius V et al (2004) Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427:537–541PubMedCrossRef
24.
Zurück zum Zitat Hall JG, Pauli RM, Wilson KM (1980) Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med 68:122–140PubMedCrossRef Hall JG, Pauli RM, Wilson KM (1980) Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med 68:122–140PubMedCrossRef
25.
Zurück zum Zitat Sugiyama T, Takaki T, Sakanaka K et al (2007) Warfarin-induced impairment of cortical bone material quality and compensatory adaptation of cortical bone structure to mechanical stimuli. J Endocrinol 194:213–222PubMedCrossRef Sugiyama T, Takaki T, Sakanaka K et al (2007) Warfarin-induced impairment of cortical bone material quality and compensatory adaptation of cortical bone structure to mechanical stimuli. J Endocrinol 194:213–222PubMedCrossRef
26.
Zurück zum Zitat Gage BF, Birman-Deych E, Radford MJ, Nilasena DS, Binder EF (2006) Risk of osteoporotic fracture in elderly patients taking warfarin: results from the national registry of atrial fibrillation 2. Arch Intern Med 166:241–246PubMedCrossRef Gage BF, Birman-Deych E, Radford MJ, Nilasena DS, Binder EF (2006) Risk of osteoporotic fracture in elderly patients taking warfarin: results from the national registry of atrial fibrillation 2. Arch Intern Med 166:241–246PubMedCrossRef
27.
Zurück zum Zitat Fennerty A, Dolben J, Thomas P et al (1984) Flexible induction dose regimen for warfarin and prediction of maintenance dose. Br Med J (Clin Res Ed) 288:1268–1270CrossRef Fennerty A, Dolben J, Thomas P et al (1984) Flexible induction dose regimen for warfarin and prediction of maintenance dose. Br Med J (Clin Res Ed) 288:1268–1270CrossRef
28.
Zurück zum Zitat Harrison L, Johnston M, Massicotte MP, Crowther M, Moffat K, Hirsh J (1997) Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med 126:133–136PubMed Harrison L, Johnston M, Massicotte MP, Crowther M, Moffat K, Hirsh J (1997) Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med 126:133–136PubMed
29.
Zurück zum Zitat Gedge J, Orme S, Hampton KK, Channer KS, Hendra TJ (2000) A comparison of a low-dose warfarin induction regimen with the modified Fennerty regimen in elderly inpatients. Age Ageing 29:31–34PubMedCrossRef Gedge J, Orme S, Hampton KK, Channer KS, Hendra TJ (2000) A comparison of a low-dose warfarin induction regimen with the modified Fennerty regimen in elderly inpatients. Age Ageing 29:31–34PubMedCrossRef
30.
Zurück zum Zitat O’Connell MB, Kowal PR, Allivato CJ, Repka TL (2000) Evaluation of warfarin initiation regimens in elderly inpatients. Pharmacotherapy 20:923–930PubMedCrossRef O’Connell MB, Kowal PR, Allivato CJ, Repka TL (2000) Evaluation of warfarin initiation regimens in elderly inpatients. Pharmacotherapy 20:923–930PubMedCrossRef
31.
Zurück zum Zitat Roberts GW, Druskeit T, Jorgensen LE et al (1999) Comparison of an age adjusted warfarin loading protocol with empirical dosing and Fennerty’s protocol. Aust N Z J Med 29:731–736PubMed Roberts GW, Druskeit T, Jorgensen LE et al (1999) Comparison of an age adjusted warfarin loading protocol with empirical dosing and Fennerty’s protocol. Aust N Z J Med 29:731–736PubMed
32.
Zurück zum Zitat Oates A, Jackson PR, Austin CA, Channer KS (1998) A new regimen for starting warfarin therapy in out-patients. Br J Clin Pharmacol 46:157–161PubMedCrossRef Oates A, Jackson PR, Austin CA, Channer KS (1998) A new regimen for starting warfarin therapy in out-patients. Br J Clin Pharmacol 46:157–161PubMedCrossRef
33.
Zurück zum Zitat Go AS, Hylek EM, Phillips KA et al (2001) Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA 285:2370–2375PubMedCrossRef Go AS, Hylek EM, Phillips KA et al (2001) Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA 285:2370–2375PubMedCrossRef
34.
Zurück zum Zitat Gage BF, Fihn SD, White RH (2001) Warfarin therapy for an octogenarian who has atrial fibrillation. Ann Intern Med 134:465–474PubMed Gage BF, Fihn SD, White RH (2001) Warfarin therapy for an octogenarian who has atrial fibrillation. Ann Intern Med 134:465–474PubMed
35.
Zurück zum Zitat Majeed A, Moser K, Carroll K (2001) Trends in the prevalence and management of atrial fibrillation in general practice in England and Wales, 1994–1998: analysis of data from the general practice research database. Heart 86:284–288PubMedCrossRef Majeed A, Moser K, Carroll K (2001) Trends in the prevalence and management of atrial fibrillation in general practice in England and Wales, 1994–1998: analysis of data from the general practice research database. Heart 86:284–288PubMedCrossRef
36.
Zurück zum Zitat Gurwitz J, Avorn J, Ross-Degnan D, Choodnovskiy I, Ansell J (1992) Aging and the anticoagulant response to warfarin therapy. Ann Intern Med 116:901–904PubMed Gurwitz J, Avorn J, Ross-Degnan D, Choodnovskiy I, Ansell J (1992) Aging and the anticoagulant response to warfarin therapy. Ann Intern Med 116:901–904PubMed
37.
Zurück zum Zitat Ageno W, Squizzato A, Dentali F, Crowther M (2005) Tailoring warfarin induction doses to reflect individual and disease-specific factors. Am J Med 118:143–144PubMedCrossRef Ageno W, Squizzato A, Dentali F, Crowther M (2005) Tailoring warfarin induction doses to reflect individual and disease-specific factors. Am J Med 118:143–144PubMedCrossRef
38.
Zurück zum Zitat Visser LE, van Vliet M, van Schaik RH et al (2004) The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Pharmacogenetics 14:27–33PubMedCrossRef Visser LE, van Vliet M, van Schaik RH et al (2004) The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Pharmacogenetics 14:27–33PubMedCrossRef
39.
Zurück zum Zitat Gage BF, Eby C, Banet G, Milligan P, McLeod H (2002) Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin (abstract). J Gen Intern Med 17:111 Gage BF, Eby C, Banet G, Milligan P, McLeod H (2002) Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin (abstract). J Gen Intern Med 17:111
40.
Zurück zum Zitat Steward DJ, Haining RL, Henne KR et al (1997) Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics 7:361–367PubMedCrossRef Steward DJ, Haining RL, Henne KR et al (1997) Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics 7:361–367PubMedCrossRef
41.
Zurück zum Zitat Takahashi H, Kashima T, Nomoto S et al (1998) Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes. Pharmacogenetics 8:356–373CrossRef Takahashi H, Kashima T, Nomoto S et al (1998) Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes. Pharmacogenetics 8:356–373CrossRef
42.
Zurück zum Zitat Tabrizi AR, Zehnbauer BA, Borecki IB, McGrath SD, Buchman TG, Freeman BD (2002) The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin. J Am Coll Surg 194:267–273PubMedCrossRef Tabrizi AR, Zehnbauer BA, Borecki IB, McGrath SD, Buchman TG, Freeman BD (2002) The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin. J Am Coll Surg 194:267–273PubMedCrossRef
43.
Zurück zum Zitat Aithal GP, Day CP, Kesteven PJL, Daly AK (1999) Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353:717–719PubMedCrossRef Aithal GP, Day CP, Kesteven PJL, Daly AK (1999) Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353:717–719PubMedCrossRef
44.
Zurück zum Zitat Kaminsky LS, de Morais SM, Faletto MB, Dunbar DA, Goldstein JA (1993) *Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe. Mol Pharmacol 43:234–239PubMed Kaminsky LS, de Morais SM, Faletto MB, Dunbar DA, Goldstein JA (1993) *Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe. Mol Pharmacol 43:234–239PubMed
45.
Zurück zum Zitat Gotoh O (1992) Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J Biol Chem 267:83–90PubMed Gotoh O (1992) Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J Biol Chem 267:83–90PubMed
46.
Zurück zum Zitat Rieder MJ, Reiner AP, Gage BF et al (2005) Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352:2285–2293PubMedCrossRef Rieder MJ, Reiner AP, Gage BF et al (2005) Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352:2285–2293PubMedCrossRef
47.
Zurück zum Zitat Marsh S, King CR, Porche-Sorbet RM, Scott-Horton TJ, Eby CS (2006) Population variation in VKORC1 haplotype structure. J Thromb Haemost 4:473–474PubMedCrossRef Marsh S, King CR, Porche-Sorbet RM, Scott-Horton TJ, Eby CS (2006) Population variation in VKORC1 haplotype structure. J Thromb Haemost 4:473–474PubMedCrossRef
48.
Zurück zum Zitat Reitsma PH, Heijden JF, Groot AP, Rosendaal FR, Buller HR (2005) A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk. PLoS Med 2:e312PubMedCrossRef Reitsma PH, Heijden JF, Groot AP, Rosendaal FR, Buller HR (2005) A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk. PLoS Med 2:e312PubMedCrossRef
49.
Zurück zum Zitat Osman A, Enstrom C, Arbring K, Soderkvist P, Lindahl TL (2006) Main haplotypes and mutational analysis of vitamin K epoxide reductase (VKORC1) in a Swedish population: a retrospective analysis of case records. J Thromb Haemost 4:1723–1729PubMedCrossRef Osman A, Enstrom C, Arbring K, Soderkvist P, Lindahl TL (2006) Main haplotypes and mutational analysis of vitamin K epoxide reductase (VKORC1) in a Swedish population: a retrospective analysis of case records. J Thromb Haemost 4:1723–1729PubMedCrossRef
50.
Zurück zum Zitat Wadelius M, Chen LY, Downes K et al (2005) Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 5:262–270PubMedCrossRef Wadelius M, Chen LY, Downes K et al (2005) Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 5:262–270PubMedCrossRef
51.
Zurück zum Zitat Sconce EA, Khan TI, Wynne HA et al (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106:2329–2333PubMedCrossRef Sconce EA, Khan TI, Wynne HA et al (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106:2329–2333PubMedCrossRef
52.
Zurück zum Zitat Loebstein R, Dvoskin I, Halkin H et al (2007) A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. Blood 109:2477–2480PubMedCrossRef Loebstein R, Dvoskin I, Halkin H et al (2007) A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. Blood 109:2477–2480PubMedCrossRef
53.
Zurück zum Zitat Shikata E, Ieiri I, Ishiguro S et al (2004) Association of pharmacokinetic (CYP2C9) and pharmacodynamic (vitamin K-dependent protein-Factors II, VII, IX, and X, proteins S and C, and {gamma}-glutamyl carboxylase) gene variants with warfarin sensitivity. Blood 103:2630–2635PubMedCrossRef Shikata E, Ieiri I, Ishiguro S et al (2004) Association of pharmacokinetic (CYP2C9) and pharmacodynamic (vitamin K-dependent protein-Factors II, VII, IX, and X, proteins S and C, and {gamma}-glutamyl carboxylase) gene variants with warfarin sensitivity. Blood 103:2630–2635PubMedCrossRef
54.
Zurück zum Zitat Chu K, Wu S, Stanley T, Stafford DW, High K (1996) A mutation in the propeptide of factor IX leads to warfarin sensitivity by a novel mechanism. J Clin Invest 98:1619–1625PubMedCrossRef Chu K, Wu S, Stanley T, Stafford DW, High K (1996) A mutation in the propeptide of factor IX leads to warfarin sensitivity by a novel mechanism. J Clin Invest 98:1619–1625PubMedCrossRef
55.
Zurück zum Zitat Oldenburg J, Quenzel EM, Harbrecht U et al (1997) Missense mutations at ALA-10 in the factor IX propeptide: an insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy. Br J Haematol 98:240–244PubMedCrossRef Oldenburg J, Quenzel EM, Harbrecht U et al (1997) Missense mutations at ALA-10 in the factor IX propeptide: an insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy. Br J Haematol 98:240–244PubMedCrossRef
56.
Zurück zum Zitat Vecsler M, Loebstein R, Almog S et al (2006) Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin. Thromb Haemost 95:205–211PubMed Vecsler M, Loebstein R, Almog S et al (2006) Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin. Thromb Haemost 95:205–211PubMed
57.
Zurück zum Zitat Wadelius M, Sorlin K, Wallerman O et al (2004) Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenomics J 4(1):40–48PubMedCrossRef Wadelius M, Sorlin K, Wallerman O et al (2004) Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenomics J 4(1):40–48PubMedCrossRef
58.
Zurück zum Zitat Millican E, Lenzini P, Milligan P et al (2007) Genetic-based dosing in orthopaedic patients beginning warfarin therapy. Blood 110:1511–1515PubMedCrossRef Millican E, Lenzini P, Milligan P et al (2007) Genetic-based dosing in orthopaedic patients beginning warfarin therapy. Blood 110:1511–1515PubMedCrossRef
Metadaten
Titel
Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues
verfasst von
Brian F. Gage
Lawrence J. Lesko
Publikationsdatum
01.02.2008
Verlag
Springer US
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 1/2008
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-007-0104-y

Weitere Artikel der Ausgabe 1/2008

Journal of Thrombosis and Thrombolysis 1/2008 Zur Ausgabe

EditorialNotes

Preface

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.